The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a manufacturer-issued press release. If approved, the release said this ...
Allergic bronchopulmonary aspergillosis is a pulmonary disease occurring in patients with asthma or cystic ... B: Bronchiectasis; CPF: Chronic pleuropulmonary fibrosis; HAM: High attenuation ...
A Prescription Drug User Fee Act target date of August 12, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application ...
The Bridgewater, N.J., biopharmaceutical company said brensocatib has the potential to become the first and only approved treatment for non-cystic fibrosis bronchiectasis, which causes the lungs ...
8monon MSN
While bronchiectasis occurs in patients with cystic fibrosis, Insmed tested brensocatib in patients with the condition who ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback